Angel N. Desai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Angel N. Desai has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Maimuna Shahnaz Majumder
Computational Health Informatics Program, Boston Children's Hospital & Harvard Medical School, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA
10 shared publications Britta Lassmann
5 shared publications- Marie-Laure Charpignon
Computational Health Informatics Program, Boston Children’s Hospital & Harvard Medical School, Boston, Massachusetts, USA
4 shared publications - Catherine Claire Pollack
Johns Hopkins University Applied Physics Laboratory, Laurel, MD, United States
3 shared publications - Divya Ramjee
Rochester Institute of Technology
3 shared publications George R. Thompson
Department of Internal Medicine, Division of Infectious Diseases, University of California Davis Health, Sacramento, CA
3 shared publications
Latest Publications
- Open Access
- 28 November 2025
- Published by Elsevier in American Journal of Infection Control
- Vol. 54 (3) , 362-363
An approach to Candidozyma auris surveillance in a low prevalence setting
- 28 November 2025
- Published by Elsevier in American Journal of Infection Control
- Vol. 54 (3) , 362-363
Open AccessAn approach to Candidozyma auris surveillance in a low prevalence setting
- Open Access
- 25 September 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 149, 107251
Oropouche virus: A re-emerging arbovirus of clinical significance
- 25 September 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 149, 107251
Open AccessOropouche virus: A re-emerging arbovirus of clinical significance
- Open Access
- 25 September 2024
- Published by Elsevier in IJID Regions
- Vol. 13, 100456
Oropouche virus: A re-emerging arbovirus of clinical significance
- 25 September 2024
- Published by Elsevier in IJID Regions
- Vol. 13, 100456
Open AccessOropouche virus: A re-emerging arbovirus of clinical significance
- Open Access
“What’s in a name?”: Using mpox as a case study to understand the importance of communication, advocacy, and information accuracy in disease nomenclature
Historically, many diseases have been named after the species or location of discovery, the discovering scientists, or the most impacted population. However, species-specific disease names often misrepresent the true reservoir; location-based disease names are frequently targeted with xenophobia; some of the discovering scientists have darker histories; and impacted populations have been stigmatized for this association. Acknowledging these concerns, the World Health Organization now proposes naming diseases after their causative pathogen or symptomatology. Recently, this guidance has been retrospectively applied to a disease at the center of an outbreak rife with stigmatization and misinformation: mpox (f.k.a. ‘monkeypox’). This disease, historically endemic to west and central Africa, has prompted racist remarks as it spread globally in 2022 in an epidemic ongoing today. Moreover, its elevated prevalence among men who have sex with men has yielded increased stigma against the LGBTQ+ community. To address these prejudicial associations, ‘monkeypox’ was renamed ‘mpox’ in November 2022. We used publicly available data from Google Search Trends to determine which countries were quicker to adopt this name change—and understand factors that limit or facilitate its use. Specifically, we built regression models to quantify the relationship between ’mpox’ search intensity in a given country and the country’s type of political regime, robustness of sociopolitical and health systems, level of pandemic preparedness, extent of gender and educational inequalities, and temporal evolution of mpox cases through December 2023. Our results suggest that, when compared to ‘monkeypox’ search intensity, ’mpox’ search intensity was significantly higher in countries with any history of mpox outbreaks or higher levels of LGBTQ+ acceptance; meanwhile, ‘mpox’ search intensity was significantly lower in countries governed by leaders who had recently propagated infectious disease misinformation. Among infectious diseases with stigmatizing names, mpox is among the first to be revised retrospectively. While the adoption of a given disease name will be context-specific—depending in part on its origins and the affected subpopulations—our study provides generalizable insights, applicable to future changes in disease nomenclature.
Open Access“What’s in a name?”: Using mpox as a case study to understand the importance of communication, advocacy, and information accuracy in disease nomenclature
Historically, many diseases have been named after the species or location of discovery, the discovering scientists, or the most impacted population. However, species-specific disease names often misrepresent the true reservoir; location-based disease names are frequently targeted with xenophobia; some of the discovering scientists have darker histories; and impacted populations have been stigmatized for this association. Acknowledging these concerns, the World Health Organization now proposes naming diseases after their causative pathogen or symptomatology. Recently, this guidance has been retrospectively applied to a disease at the center of an outbreak rife with stigmatization and misinformation: mpox (f.k.a. ‘monkeypox’). This disease, historically endemic to west and central Africa, has prompted racist remarks as it spread globally in 2022 in an epidemic ongoing today. Moreover, its elevated prevalence among men who have sex with men has yielded increased stigma against the LGBTQ+ community. To address these prejudicial associations, ‘monkeypox’ was renamed ‘mpox’ in November 2022. We used publicly available data from Google Search Trends to determine which countries were quicker to adopt this name change—and understand factors that limit or facilitate its use. Specifically, we built regression models to quantify the relationship between ’mpox’ search intensity in a given country and the country’s type of political regime, robustness of sociopolitical and health systems, level of pandemic preparedness, extent of gender and educational inequalities, and temporal evolution of mpox cases through December 2023. Our results suggest that, when compared to ‘monkeypox’ search intensity, ’mpox’ search intensity was significantly higher in countries with any history of mpox outbreaks or higher levels of LGBTQ+ acceptance; meanwhile, ‘mpox’ search intensity was significantly lower in countries governed by leaders who had recently propagated infectious disease misinformation. Among infectious diseases with stigmatizing names, mpox is among the first to be revised retrospectively. While the adoption of a given disease name will be context-specific—depending in part on its origins and the affected subpopulations—our study provides generalizable insights, applicable to future changes in disease nomenclature.
- Open Access
- 26 April 2024
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 110 (1) , 116334
Utility of microbial cell free DNA next-generation sequencing for diagnosis and management of infectious diseases
- 26 April 2024
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 110 (1) , 116334
Open AccessUtility of microbial cell free DNA next-generation sequencing for diagnosis and management of infectious diseases
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1219. Utility of Plasma Microbial Cell-Free DNA Testing for Therapeutic Management and Antimicrobial Stewardship
Microbial cell-free DNA (mcfDNA) sequencing is a promising potential tool in the detection of infectious pathogens when traditional methods fail to identify the causative agent. It may be particularly helpful in identifying pathogens that are present at low levels or that do not grow well in standard culture. The aim of this study was to determine whether plasma mcfDNA sequencing resulted in a change in therapeutic management. A retrospective cohort at UC Davis Medical Center was reviewed. All patients, both pediatric and adult, that underwent plasma mcfDNA (Karius) sequencing between December 11th, 2019, and January 4th, 2023, were included. Patient demographics, comorbid conditions, immunocompromised status, indication for testing, pre and post antimicrobial therapies from when the sample was collected, pathogen identified, ID consultation status, and ordering service at the time of testing were recorded. Each patient was analyzed by two independent reviewers for clinically significant microbial findings, treatment, and reviewer concordance with therapeutic management. If discordance between reviewers was present, a third reviewer analyzed the data. A total of 127 Karius tests were reviewed from 71 patients. Baseline characteristics included 62 (48%) pediatric and 65 (51%) adult tests. 25 (33%) tests were from female patients, and 37 tests (50%) were obtained from immunocompromised patients. The most frequent adult ordering services included the Medical Intensive Care Unit and Bone Marrow Transplant Unit. The most frequent pediatric ordering services included the Pediatric Intensive Care Unit followed by General Pediatrics. 69 (95%) of tests had a formal Infectious Diseases consultation associated with testing. 22 (30%) tests resulted in a change in antimicrobial therapy, and 35 (47%) of tests resulted in a clinically significant organism. In this retrospective cohort study conducted at a single center, Karius testing resulted in clinically significant pathogens in less than half of all tests conducted, and most test results did not lead to a change in therapeutic management. Testing in certain clinical scenarios or high-risk settings may be warranted, however further studies are needed. George R. Thompson, III, MD, Astellas: Advisor/Consultant|Astellas: Grant/Research Support|Cidara: Advisor/Consultant|Cidara: Grant/Research Support|F2G: Advisor/Consultant|F2G: Grant/Research Support|Mayne: Advisor/Consultant|Mayne: Grant/Research Support|Melinta: Advisor/Consultant|Melinta: Grant/Research Support|Mundipharma: Advisor/Consultant|Mundipharma: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1219. Utility of Plasma Microbial Cell-Free DNA Testing for Therapeutic Management and Antimicrobial Stewardship
Microbial cell-free DNA (mcfDNA) sequencing is a promising potential tool in the detection of infectious pathogens when traditional methods fail to identify the causative agent. It may be particularly helpful in identifying pathogens that are present at low levels or that do not grow well in standard culture. The aim of this study was to determine whether plasma mcfDNA sequencing resulted in a change in therapeutic management. A retrospective cohort at UC Davis Medical Center was reviewed. All patients, both pediatric and adult, that underwent plasma mcfDNA (Karius) sequencing between December 11th, 2019, and January 4th, 2023, were included. Patient demographics, comorbid conditions, immunocompromised status, indication for testing, pre and post antimicrobial therapies from when the sample was collected, pathogen identified, ID consultation status, and ordering service at the time of testing were recorded. Each patient was analyzed by two independent reviewers for clinically significant microbial findings, treatment, and reviewer concordance with therapeutic management. If discordance between reviewers was present, a third reviewer analyzed the data. A total of 127 Karius tests were reviewed from 71 patients. Baseline characteristics included 62 (48%) pediatric and 65 (51%) adult tests. 25 (33%) tests were from female patients, and 37 tests (50%) were obtained from immunocompromised patients. The most frequent adult ordering services included the Medical Intensive Care Unit and Bone Marrow Transplant Unit. The most frequent pediatric ordering services included the Pediatric Intensive Care Unit followed by General Pediatrics. 69 (95%) of tests had a formal Infectious Diseases consultation associated with testing. 22 (30%) tests resulted in a change in antimicrobial therapy, and 35 (47%) of tests resulted in a clinically significant organism. In this retrospective cohort study conducted at a single center, Karius testing resulted in clinically significant pathogens in less than half of all tests conducted, and most test results did not lead to a change in therapeutic management. Testing in certain clinical scenarios or high-risk settings may be warranted, however further studies are needed. George R. Thompson, III, MD, Astellas: Advisor/Consultant|Astellas: Grant/Research Support|Cidara: Advisor/Consultant|Cidara: Grant/Research Support|F2G: Advisor/Consultant|F2G: Grant/Research Support|Mayne: Advisor/Consultant|Mayne: Grant/Research Support|Melinta: Advisor/Consultant|Melinta: Grant/Research Support|Mundipharma: Advisor/Consultant|Mundipharma: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support
- Open Access
A Mixed-Effects Model to Predict COVID-19 Hospitalizations Using Wastewater Surveillance
During the COVID-19 pandemic, many countries and regions investigated the potential use of wastewater-based disease surveillance as an early warning system. Initially, methods were created to detect the presence of SARS-CoV-2 RNA in wastewater. Investigators have since conducted extensive studies to examine the link between viral concentration in wastewater and COVID-19 cases in areas served by sewage treatment plants over time. However, only a few reports have attempted to create predictive models for hospitalizations at county-level based on SARS-CoV-2 RNA concentrations in wastewater. This study implemented a linear mixed-effects model that observes the association between levels of virus in wastewater and county-level hospitalizations. The model was then utilized to predict short-term county-level hospitalization trends in 21 counties in California based on data from March 21, 2022, to May 21, 2023. The modeling framework proposed here permits repeated measurements as well as fixed and random effects. The model that assumed wastewater data as an input variable, instead of cases or test positivity rate, showed strong performance and successfully captured trends in hospitalizations. Additionally, the model allows for the prediction of SARS-CoV-2 hospitalizations two weeks ahead. Forecasts of COVID-19 hospitalizations could provide crucial information for hospitals to better allocate resources and prepare for potential surges in patient numbers.
Open AccessA Mixed-Effects Model to Predict COVID-19 Hospitalizations Using Wastewater Surveillance
During the COVID-19 pandemic, many countries and regions investigated the potential use of wastewater-based disease surveillance as an early warning system. Initially, methods were created to detect the presence of SARS-CoV-2 RNA in wastewater. Investigators have since conducted extensive studies to examine the link between viral concentration in wastewater and COVID-19 cases in areas served by sewage treatment plants over time. However, only a few reports have attempted to create predictive models for hospitalizations at county-level based on SARS-CoV-2 RNA concentrations in wastewater. This study implemented a linear mixed-effects model that observes the association between levels of virus in wastewater and county-level hospitalizations. The model was then utilized to predict short-term county-level hospitalization trends in 21 counties in California based on data from March 21, 2022, to May 21, 2023. The modeling framework proposed here permits repeated measurements as well as fixed and random effects. The model that assumed wastewater data as an input variable, instead of cases or test positivity rate, showed strong performance and successfully captured trends in hospitalizations. Additionally, the model allows for the prediction of SARS-CoV-2 hospitalizations two weeks ahead. Forecasts of COVID-19 hospitalizations could provide crucial information for hospitals to better allocate resources and prepare for potential surges in patient numbers.
- Open Access
- 27 February 2023
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 25, e40706
Evolving Face Mask Guidance During a Pandemic and Potential Harm to Public Perception: Infodemiology Study of Sentiment and Emotion on Twitter
Background: Throughout the COVID-19 pandemic, US Centers for Disease Control and Prevention policies on face mask use fluctuated. Understanding how public health communications evolve around key policy decisions may inform future decisions on preventative measures by aiding the design of communication strategies (eg, wording, timing, and channel) that ensure rapid dissemination and maximize both widespread adoption and sustained adherence. Objective: We aimed to assess how sentiment on masks evolved surrounding 2 changes to mask guidelines: (1) the recommendation for mask use on April 3, 2020, and (2) the relaxation of mask use on May 13, 2021. Methods: We applied an interrupted time series method to US Twitter data surrounding each guideline change. Outcomes were changes in the (1) proportion of positive, negative, and neutral tweets and (2) number of words within a tweet tagged with a given emotion (eg, trust). Results were compared to COVID-19 Twitter data without mask keywords for the same period. Results: There were fewer neutral mask-related tweets in 2020 (β=–3.94 percentage points, 95% CI –4.68 to –3.21; P<.001) and 2021 (β=–8.74, 95% CI –9.31 to –8.17; P<.001). Following the April 3 recommendation (β=.51, 95% CI .43-.59; P<.001) and May 13 relaxation (β=3.43, 95% CI 1.61-5.26; P<.001), the percent of negative mask-related tweets increased. The quantity of trust-related terms decreased following the policy change on April 3 (β=–.004, 95% CI –.004 to –.003; P<.001) and May 13 (β=–.001, 95% CI –.002 to 0; P=.008). Conclusions: The US Twitter population responded negatively and with less trust following guideline shifts related to masking, regardless of whether the guidelines recommended or relaxed mask usage. Federal agencies should ensure that changes in public health recommendations are communicated concisely and rapidly.
- 27 February 2023
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 25, e40706
Open AccessEvolving Face Mask Guidance During a Pandemic and Potential Harm to Public Perception: Infodemiology Study of Sentiment and Emotion on Twitter
Background: Throughout the COVID-19 pandemic, US Centers for Disease Control and Prevention policies on face mask use fluctuated. Understanding how public health communications evolve around key policy decisions may inform future decisions on preventative measures by aiding the design of communication strategies (eg, wording, timing, and channel) that ensure rapid dissemination and maximize both widespread adoption and sustained adherence. Objective: We aimed to assess how sentiment on masks evolved surrounding 2 changes to mask guidelines: (1) the recommendation for mask use on April 3, 2020, and (2) the relaxation of mask use on May 13, 2021. Methods: We applied an interrupted time series method to US Twitter data surrounding each guideline change. Outcomes were changes in the (1) proportion of positive, negative, and neutral tweets and (2) number of words within a tweet tagged with a given emotion (eg, trust). Results were compared to COVID-19 Twitter data without mask keywords for the same period. Results: There were fewer neutral mask-related tweets in 2020 (β=–3.94 percentage points, 95% CI –4.68 to –3.21; P<.001) and 2021 (β=–8.74, 95% CI –9.31 to –8.17; P<.001). Following the April 3 recommendation (β=.51, 95% CI .43-.59; P<.001) and May 13 relaxation (β=3.43, 95% CI 1.61-5.26; P<.001), the percent of negative mask-related tweets increased. The quantity of trust-related terms decreased following the policy change on April 3 (β=–.004, 95% CI –.004 to –.003; P<.001) and May 13 (β=–.001, 95% CI –.002 to 0; P=.008). Conclusions: The US Twitter population responded negatively and with less trust following guideline shifts related to masking, regardless of whether the guidelines recommended or relaxed mask usage. Federal agencies should ensure that changes in public health recommendations are communicated concisely and rapidly.
- Open Access
- 1 February 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (2) , ofad003
Mpox Infection in Children—Infection Control Implications for Household Contacts
Mpox has recently re-emerged as a global entity of concern. We report one of the first pediatric cases in the United States and provide updated recommendations relevant to infection control and prevention measures of those in close contact with mpox.
- 1 February 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (2) , ofad003
Open AccessMpox Infection in Children—Infection Control Implications for Household Contacts
Mpox has recently re-emerged as a global entity of concern. We report one of the first pediatric cases in the United States and provide updated recommendations relevant to infection control and prevention measures of those in close contact with mpox.
- Open Access
- 22 August 2022
- Published by American Medical Association (AMA) in JAMA
- Vol. 328 (13) , 1348-1350
Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection
Monkeypox is a zoonotic orthopoxvirus in the same genus as variola (the causative agent of smallpox).1 A recent global outbreak has led to more than 39 000 cases reported as of August 18, 2022.2 Monkeypox is typically self-limited with symptoms generally lasting between 2 and 4 weeks in prior outbreaks. Hospitalization was required in 13% of patients in a recent study, suggesting the need for effective therapy.3
- 22 August 2022
- Published by American Medical Association (AMA) in JAMA
- Vol. 328 (13) , 1348-1350
Open AccessCompassionate Use of Tecovirimat for the Treatment of Monkeypox Infection
Monkeypox is a zoonotic orthopoxvirus in the same genus as variola (the causative agent of smallpox).1 A recent global outbreak has led to more than 39 000 cases reported as of August 18, 2022.2 Monkeypox is typically self-limited with symptoms generally lasting between 2 and 4 weeks in prior outbreaks. Hospitalization was required in 13% of patients in a recent study, suggesting the need for effective therapy.3